Abstract
It is well established that the β2-adrenergic receptor (β2-AR) exhibits a robust ligand-independent activity, whereas this property is considerably weaker in the closely related β1-AR subtype. To identify the potential domain(s) of β2-AR responsible for the spontaneous receptor activation, we created three chimeras in which the third intracellular loop (β1/β2-Li3) or the carboxyl terminus (β1/β2-CT) or both domains (β1/β2-Li3CT) of β1-AR are replaced by the corresponding parts of the β2-AR. Using adenoviral gene transfer, we individually expressed these β1/β2-AR chimeras in mouse cardiomyocytes lacking both native β1-AR and β2-AR (β1/β2 double knockout), and examined their possible spontaneous activities. Overexpression of these β1/β2-AR chimeras markedly elevated basal cAMP accumulation and myocyte contractility in the absence of agonist stimulation compared with those infected by a control adenovirus expressing β-galactosidase or an adenovirus expressing wild type β1-AR. These effects were fully reversed by a β2-AR inverse agonist, (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol (ICI 118,551; 5 × 10-7 M), regardless of inhibition of Gi with pertussis toxin, but not by a panel of β1-AR antagonists, including [2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(1-methyl-4-trifluormethyl-2-imidazolyl)-phenoxy]-2-propanolmethanesulfonate (CGP20712A), betaxolol, bisoprolol, and metoprolol. Furthermore, we have shown that the C-terminal postsynaptic density 95/disc-large/ZO-1 (PDZ) motif of β1-AR is not responsible for the lack of β1-AR spontaneous activation, although it has been known that the β1-AR PDZ motif prevents the receptor from undergoing agonist-induced trafficking and Gi coupling in cardiomyocytes. Taken together, the present results indicate that both the third intracellular loop and the C terminus are involved in β2-AR spontaneous activation and that either domain seems to be sufficient to confer the receptor spontaneous activity.
- Received April 4, 2003.
- Accepted July 25, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|